buprenorphine hydrochloride and naloxone hydrochloride dihydrate
- Product NDC
- 71335-1720
- 11-digit product format
- 713351720
- Labeler code
- 71335
- Product ID
- 71335-1720_e8fe83a6-8661-4761-a008-1ec659eb31e8
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- buprenorphine hydrochloride and naloxone hydrochloride dihydrate
- Dosage form
- TABLET
- Route
- SUBLINGUAL
- Labeler
- Bryant Ranch Prepack
- Application
- ANDA203326
- Marketing category
- ANDA
- Marketing start
- 2014-06-27
- Substance
- BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE DIHYDRATE
- Active strength
- 2; .5 mg/1; mg/1
- Pharmacologic classes
- Opioid Antagonist [EPC], Opioid Antagonists [MoA], Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]
- DEA schedule
- CIII
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Dataset | Scope | Package NDC | Snapshot | Source SHA-256 |
|---|---|---|---|---|---|
| 2024-05-15 03:39 UTC · source 2024-05-14 | excluded product | product | 834df4deac94… | adcc014656a3… | |
| 2024-05-15 03:39 UTC · source 2024-05-14 | excluded package | package | 71335-1720-1 | 834df4deac94… | adcc014656a3… |
| 2024-05-15 03:39 UTC · source 2024-05-14 | excluded package | package | 71335-1720-2 | 834df4deac94… | adcc014656a3… |
| 2024-03-11 06:39 UTC · source 2024-03-08 | excluded product | product | 1332a3947898… | d4bfe170f9cd… | |
| 2024-03-11 06:39 UTC · source 2024-03-08 | excluded package | package | 71335-1720-1 | 1332a3947898… | d4bfe170f9cd… |
| 2024-03-11 06:39 UTC · source 2024-03-08 | excluded package | package | 71335-1720-2 | 1332a3947898… | d4bfe170f9cd… |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | |
| A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203326-001 | AB |
| A203326-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | RS | 2014-06-27 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A203326-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | A203326-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2014-06-27 | 782e0a99824c… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A203326-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A203326-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203326-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203326-002 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203326-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A203326-002 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203326-001 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203326-002 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203326-001 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203326-002 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203326-001 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203326-002 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203326-001 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203326-002 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203326-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203326-002 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203326-001 | AB | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203326-002 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A203326-001 | AB | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A203326-002 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203326-001 | AB | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203326-002 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203326-001 | AB | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203326-002 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203326-001 | AB | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203326-002 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A203326-001 | AB | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A203326-002 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203326-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203326-002 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A203326-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A203326-002 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A203326-001 | AB | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A203326-002 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A203326-001 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A203326-002 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A203326-001 | AB | 1 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | A203326-002 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A203326-001 | AB | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | A203326-002 | AB | 1 | 782e0a99824c… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- buprenorphine hydrochloride and naloxone hydrochloride dihydrate
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| BUPRENORPHINE HYDROCHLORIDE | 2 mg/1 |
| NALOXONE HYDROCHLORIDE DIHYDRATE | .5 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 56W8MW3EN1 | Internal UNII lookup |
| 5Q187997EE | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 351266 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | Available on FDA.report |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71335-1720-1 | buprenorphine hydrochloride and naloxone hydrochloride dihydrate | 30 in 1 BOTTLE | TABLET | 30 | 106 | |
| 71335-1720-2 | buprenorphine hydrochloride and naloxone hydrochloride dihydrate | 10 in 1 BOTTLE | TABLET | 10 | 106 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 71335-1720 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE TABLET [BRYANT RANCH PREPACK] | 105 | Current NDC, Legacy NDC, 2 package rows | 20240824_a0f8c28c-ed9a-4a26-91a3-b996c117ac2c.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| buprenorphine and naloxone | BUPRENORPHINE AND NALOXONE | Hikma Pharmaceuticals USA Inc. | 713db2c6-0544-4633-b874-cfbeaf93db89 | 2026-07-26 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | REMEDYREPACK INC. | 43027750-d218-49e5-867f-c941736d2056 | 2026-06-10 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | REMEDYREPACK INC. | 4124c4ad-ef62-4c95-8e57-0d843862ae71 | 2026-06-09 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | 2026-05-14 | Warnings, Adverse reactions | 203326 ANDA203326 71335-1720 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | d25b1a73-9794-4e86-82eb-dee3f159a214 | 2026-05-13 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Golden State Medical Supply, Inc. | 4f6e0056-b19d-0d0e-e063-6294a90a16e5 | 2026-04-24 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 99a5b62f-bc08-44f4-abb8-300520d2162a | 2026-03-06 | Warnings, Adverse reactions | 203326 ANDA203326 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Major Pharmaceuticals | c5fbec69-e7de-44a8-b9fa-0378ae61a9fe | 2026-03-03 | Warnings, Adverse reactions | 203326 ANDA203326 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 351266 | buprenorphine HCl 2 MG / naloxone HCl 0.5 MG Sublingual Tablet | PSN | a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | 106 |
| 351266 | buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet | SCD | a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | 106 |
| 351266 | buprenorphine 2 MG (as buprenorphine HCl) / naloxone 0.5 MG (as naloxone HCl) Sublingual Tablet | SY | a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | 106 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 71335-1720-1 | 71335172001 | 30 TABLET in 1 BOTTLE (71335-1720-1) | 30 tablet | 2020-10-19 | 0000-00-00 | No | No | Current |
| 71335-1720-2 | 71335172002 | 10 TABLET in 1 BOTTLE (71335-1720-2) | 10 tablet | 2024-08-12 | 0000-00-00 | No | No | Current |